aTyr Pharma Inc.'s management held an investor call on September 15, 2025, during which they announced that the EFZO-FIT study did not meet its primary endpoint. Specifically, the company disclosed that the study failed to achieve a significant change from baseline in mean daily OSC dose at week 48. Following this announcement, the company stated that it would engage with the FDA to determine the next steps in light of the disappointing topline results. The full podcast discussing the class action lawsuit related to these developments is available at https://www.podbean.com/player-v2/?i=mj5ct-19ad352-pb&from=pb6admin&pbad=0&share=1&download=1&rtl=0&fonts=Arial&skin=1&font-color=auto&logo_link=episode_page&btn-skin=7.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1115006) on December 05, 2025, and is solely responsible for the information contained therein.